Insight

Jarushka Naidoo: Interesting multi-omic analysis of previously classified SCLC cell lines

Photo taken from aacrjournals.org

May 9, 2024, 14:13

Jarushka Naidoo: Interesting multi-omic analysis of previously classified SCLC cell lines

Jarushka Naidoo shared a post on X:

“Interesting multi-omic analysis of previously classified Small Cell Lung Cancer (SCLC) cell lines (YAP1+), identifies that these tumors represent diseases that ‘mimic’ SCLC- in this case- SMARCA4-deficient thoracic tumors, that have a poor prognosis.”

Additional information.
Source: Jarushka Naidoo/X

Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.

Ahida Batrouney Ariena J. Kersbergen cancer Christine Khoo Danielle K. Boyd David J. Byrne Jarushka Naidoo Jin Ng John D. Minna Johns Hopkins University Kate D. Sutherland Ling Cai! Luc Girard Marian L. Burr Michael Christie Neeha Rajan OncoDaily Oncology Owen W.J. Prall SCLC small cell lung cancer SMARCA4 thoracic tumors

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Isabel Mestres: In a world where the fight against cancer knows no borders, collaboration is not optional - it’s essential

Special Coverage